Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BURnOUT

Financiado

Enabling efficient cell engineering leaving gene-expression BURden OUT for cell...

Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industry Mammalian cell engineering has emerged as a new ground-breaking modality for the development of cell based therapies to treat several hard-to-cure diseases, including cancer (T cell-based immunotherapies) and to produce molecule w... ver más

28/02/2026

IIT

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-13

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

IIT

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PLEC2023-010243 Herramientas diagnósticas, pronósticas y terapéuticas 539K€ Cerrado

PTQ-16-08393 Desarrollo de anticuerpos mediante técnicas in silico e inte... 83K€ Cerrado

LUCERO-BIO LUCERO BIO: Smart Optofluidic Isolation of Spheroids for Ear... 1M€ Cerrado

COBIOE GROWING CONNECTION FOR BIO ECOSYSTEMS 500K€ Cerrado

CoDiBio Continuous Digitalized Processes for Producing Biopharmaceut... 3M€ Cerrado

BIO2008-06505 PRODUCCION Y PURIFICACION DE ANTICUERPOS MONOCLONALES HUMANO... 151K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2024-02-13
Fecha Fin: 2026-02-28

Líder del proyecto

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Mammalian cell engineering has emerged as a new ground-breaking modality for the development of cell based therapies to treat several hard-to-cure diseases, including cancer (T cell-based immunotherapies) and to produce molecule with diagnostic and therapeutic applications such as monoclonal antibodies (mAbs), that are now a dominant product class in the biopharmaceutical industry. However, the pipeline for efficient design-test-commercialization of the product is long and expensive, even more so when cells must be engineered with two or more transgenes, an increasing need in T cell-based therapies or drug production (e.g., cells engineered to produce enzyme and co-enzymes, or antibody cocktails). At the core of the problem is the competition for a finite number of intracellular resources, transcriptional and translational, that cause an unbalanced expression of products thus hampering the therapeutic effect. BURnOUT is an Artificial Intelligence and Machine Learning based software that will provide, in an automated manner, paired gene sequence optimisation to accelerate the process of mammalian cell engineering. BURnOUT will be validated in two different settings: one for the biopharmaceutics (engineered CHO cell lines for antibodies production) and one for cell therapy (engineering T cells for multiple CARs expression). The successful validation of the technology will be of trans-and multi-disciplinary interest and will have the goal of targeting the amplest variety of markets in Life Science, from AI to synthetic biology for cell and gene therapies and global cell technologies for drug industry. We envision that BURnOUT will respond to current strategic societal needs and challenges such as reduced costs of biopharmaceutics, and more effective treatment for cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores